Mateon Therapeutics, Inc. (MATN)

Oncology Corporate Profile

Stock Performance

0.2410
-0.0190

3 Month Stock History Chart

HQ Location

701 Gateway Blvd, Suite 210
San Francisco, CA 94080

Company Description

Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These 2 approaches (VDAs and AAs) have distinct yet complementary mechanisms of action. At Mateon, we believe that we can significantly improve cancer therapy by combining these 2 complementary approaches.

Website: http://www.mateon.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
fosbretabulin (+ bevacizumab) / CA4Ptubulin-binding vascular disrupting agent (VDA)Glioblastoma Multiforme (GBM)II
fosbretabulin (+ bevacizumab) / CA4Ptubulin-binding vascular disrupting agent (VDA)Ovarian cancerII
fosbretabulin (+ bevacizumab and PCC) / CA4Ptubulin-binding vascular disrupting agent (VDA)Platinum-resistant Ovarian cancerII
OXi4503 (+cytarabine)dual-mechanism vascular disrupting agent (VDA)Myelodysplastic Syndrome (MDS)I
fosbretabulin (+ pazopanib) / CA4Ptubulin-binding vascular disrupting agent (VDA)Ovarian cancerI

Source: http://www.mateon.com/

Recent News Headlines

8/21/2017 06:21 am

8/21/2017 06:21 am

8/16/2017 06:18 am

8/16/2017 06:18 am

8/6/2017 12:24 pm

8/2/2017 12:19 pm

8/1/2017 12:23 am

8/1/2017 12:23 am

7/31/2017 06:22 am

6/28/2017 06:18 am

6/12/2017 06:19 am

6/12/2017 06:19 am

6/7/2017 06:18 am

6/7/2017 06:18 am

5/8/2017 12:19 pm

4/27/2017 06:18 am

4/20/2017 06:18 am

4/19/2017 06:18 am

4/18/2017 06:18 am

Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017

3/31/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 31, 2017-- Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced ...

Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results

3/30/2017 12:03 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 30, 2017-- Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today provided ...

Mateon Therapeutics Announces Initial Data from Third Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML

3/15/2017 12:00 pm

[GlobeNewswire] - One patient of four achieved a complete remission No dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif., March 15, 2017-- Mateon Therapeutics, ...

Mateon Therapeutics to Present at 29th Annual ROTH Conference

3/8/2017 02:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 08, 2017-- Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced ...